Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366494 · ClinicalTrials.gov registry record
Micro RNAs to Predict Response to Androgen Deprivation Therapy
A clinical trial of Prostate Cancer, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT02366494 is a study of Prostate Cancer that has completed, run by Medical College of Wisconsin. The registered enrollment target is 42 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02366494, a study of Prostate Cancer, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Identify exosomal micro RNA that predict responses to ADT
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Goserelin
- DRUG Bicalutamide
- DRUG Leuprolide
- DRUG Triptorelin
Study Locations (1)
Wisconsin
- Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-04-29 |
| Est. Completion | 2021-05-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366494
The ClinicalTrials.gov registry entry for NCT02366494 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT02366494 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02366494 about?
NCT02366494 is a clinical study titled "Micro RNAs to Predict Response to Androgen Deprivation Therapy". Identify exosomal micro RNA that predict responses to ADT
What is the current status of trial NCT02366494?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-04-29. Estimated completion is 2021-05-11.
What conditions does trial NCT02366494 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02366494?
The interventions under investigation include: Docetaxel (DRUG), Goserelin (DRUG), Bicalutamide (DRUG), Leuprolide (DRUG), Triptorelin (DRUG).
Who is sponsoring clinical trial NCT02366494?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366494 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.